human menopausal gonadotropin
PreclinicalSmall molecule
EMD Seronohuman menopausal gonadotropin is one of 94 small molecule programs targeting Polycystic Ovary Syndrome. It is currently in Preclinical.
4
Indications
11
Total Trials
0
Active Trials
93
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
72 competitors in Polycystic Ovary Syndrome
#DrugCompanyPhaseTrials
1Glucophage
EMD SeronoApproved
Femara
NovartisApproved
Avandia
Jazz PharmaceuticalsApproved
Myrbetriq
AstellasApproved
Daliresp
AstraZenecaApproved
Evista
Eli LillyApproved
Calciferol
Jazz PharmaceuticalsApproved
Alli
EEngelhard Arzneimittel GmbH & Co.KG
Approved
Topamax
WWim Janssens
Approved
Tradjenta
Boehringer IngelheimApproved
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Hypogonadotropic Hypogonadism2 trials
Embryo1 trial
Ovarian1 trial
Oocyte1 trial
The Value of Addition of Human Menopausal Gonadotropin Drug Following Oocytes Retrieval in IVF Cycles
Completed·—·Phase 4·NCT03209687·600 enrolled
Pregnancy1 trial
Cumulative Pregnancy Rate With Lower and Higher Gonadotropin Dose During IVF Among Poor Responders
Completed·—·N/A·NCT05103228·190 enrolled
5 more indications
Ovarian Reserve1 trial
Predictors of Ovarian Reserve in Infertile Women
Unknown status·—·Phase 4·NCT02896023·100 enrolled
Ovarian Stimulation1 trial
Polycystic Ovary Syndrome1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Preclinical[1]
- Company